Focused engagement
Translational, Biomarker & Immunogenicity Analytics
Reproducible analysis that connects molecular, assay and clinical information without obscuring uncertainty or exploratory status.
When to use it
Best fit
Translational medicine, R&D and biometrics teams working with biomarkers, immunogenicity, single-cell or other omics data.
Scope
- Assess assay, molecular and clinical metadata and define an analysis-ready structure.
- Perform targeted QC, exploratory analysis and agreed biomarker or immunogenicity methods.
- Integrate molecular signals with treatment, response or clinical endpoints.
- Control multiplicity and distinguish exploratory from confirmatory claims.
Inputs
- Molecular, biomarker or immunogenicity data and data dictionary.
- Clinical metadata, endpoint definitions and treatment or visit structure.
- Assay rules, limits of quantification and sample annotation where relevant.
- Scientific questions and prior analyses.
Deliverables
- QC and exploratory-analysis report.
- Results tables and decision-focused visualisations.
- Reproducible scripts or pipeline and methods documentation.
- Assumptions, limitations and recommended next analyses.
Data handling
Real patient or confidential study data remains within the client, sponsor, CRO or contractually approved environment. The permitted data, access model and retention rules are agreed before work begins.
Do not send patient, clinical or confidential study data.
Boundaries
- Does not include wet-lab or assay validation, clinical adjudication or regulatory biomarker qualification.
- Exploratory results are not presented as validated biomarkers or confirmatory evidence.
- Enterprise infrastructure and full manuscript writing require separate scope.
Discuss this engagement
Confirm fit before sharing materials.
Begin with the study situation, intended decision and timing. Data access is agreed only after scope and safeguards are defined.